Alexandria Raises Full-year Outlook; Signs A 15-year Full Binding Lease With Moderna

California-based real estate company Alexandria Real Estate Equities, Inc. (ARE), on Monday raised its full-year earnings outlook to $3.91 to $3.93 per share.

On an adjusted basis, the company forecast for the earnings is between $7.74 and $7.76 per share.

On average, seven analysts polled by Thomson Reuters are expecting earnings of $3.78 per share for the full year.

Previously, the company expected earnings of $3.46 to $3.54 per share, or $7.71 to $7.79 per share excluding special items.

Alexandria also reported signing a 15-year deal with a pharmaceutical company, Moderna, Inc (MRNA) to construct, develop and manage the company’s research and development facility at 325 Binney Street.

The facility is going to be a 462,100 RSF property and will also be the most sustainable laboratory facility in Cambridge. This is the biggest life-science deal Alexandria Real Estate has signed in the history of the company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT